156706-47-7|546C88|Nw-methyl-L-arginine hydrochloride|-范德生物科技公司

546C88

NMR下载 COA and HPLC MSDS下载
names：
Nw-methyl-L-arginine hydrochloride
CAS号：
156706-47-7
MDL Number：
MF(分子式)： C7H17ClN4O2 MW(分子量)： 224.68
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	546C88
英文别名	546C88; L-NMMA; NG-Monomethyl-L-arginine hydrochloride; L-N(G)-Methylarginine hydrochloride;
CAS号	156706-47-7
Inchi	InChI=1S/C7H16N4O2.ClH/c1-10-7(9)11-4-2-3-5(8)6(12)13;/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11);1H/t5-;/m0./s1
InchiKey	QYGXVJHXZUSLQC-JEDNCBNOSA-N
分子式 Formula	C7H17ClN4O2
分子量 Molecular Weight	224.68
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	546C88(CAS:156706-47-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	546C88 is a nitric oxide synthase inhibitor.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Schwartz S, Clare R, Devereux K, Sheung CF. Pharmacokinetics, disposition and metabolism of 546C88 (L-NG-methylarginine hydrochloride) in rat and dog. Xenobiotica. 1997 Dec;27(12):1259-7[1]PubMed PMID: 9460231.

[2]Cooper JD, Shearsby N, Sheung CT. Use of the ASTED system to determine L-NG-monomethylarginine (546C88) in human plasma by pre-column o-phthalaldehyde derivatisation and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997 Aug 15;696(1):117-22. PubMed PMID: 9300915.

[3] López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004 Jan;32(1):21-30. PubMed PMID: 14707556.

[4] Watson D, Grover R, Anzueto A, Lorente J, Smithies M, Bellomo R, Guntupalli K, Grossman S, Donaldson J, Le Gall JR; Glaxo Wellcome International Septic Shock Study Group. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004 Jan;32(1):13-20. PubMed PMID: 14707555.

[5] Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J; Glaxo Wellcome International Septic Shock Study Group. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004 Jan;32(1):1-12. PubMed PMID: 14707554.

6: Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med. 1999 May;27(5):913-22. PubMed PMID: 10362413.7: Renes MH, van der Hoeven JG. Administration of nitric oxide synthase inhibitor 546C88 in septic shock. Crit Care Med. 2004 Jul;32(7):1625; author reply 1625-6. PubMed PMID: 15241124.8: Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J, Olesen J. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia. 1998 Jan;18(1):27-32. PubMed PMID: 9601621.9: Harrison RW, Thakkar RN, Senzaki H, Ekelund UE, Cho E, Kass DA, Hare JM. Relative contribution of preload and afterload to the reduction in cardiac output caused by nitric oxide synthase inhibition with L-N(G)-methylarginine hydrochloride 546C88. Crit Care Med. 2000 May;28(5):1263-8. PubMed PMID: 10834663.10: Lassen Lh, Sperling B, Andersen Ar, Olesen J. The effect of i.v. L-NG methylarginine hydrochloride (L-NMMA: 546C88) on basal and acetazolamide (Diamox) induced changes of blood velocity in cerebral arteries and regional cerebral blood flow in man. Cephalalgia. 2005 May;25(5):344-52. PubMed PMID: 15839849.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开